JP Morgan Chase
GTBP icon

JP Morgan Chase’s GT Biopharma GTBP Stock Holding History

JP Morgan Chase’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 7879
2026
Q1 		– Hold
0
– – – 7682
2025
Q4 		– Hold
0
– – – 7379
2025
Q3 		– Hold
0
– – – 7354
2025
Q2 		– Hold
0
– – – 7004
2025
Q1 		– Hold
0
– – – 7251
2024
Q4 		– Hold
0
– – – 7346
2024
Q3 		– Hold
0
– – – 7355
2024
Q2 		– Hold
0
– – – 7264
2024
Q1 		– Hold
0
– – – 7281
2023
Q4 		– Hold
0
– – – 7456
2023
Q3 		– Sell
-3
Closed -$620 – 7245
2023
Q2 		$810 Buy
+3
New +$778 ﹤0.01% 6486
2023
Q1 		– Hold
0
– – – 6921
2022
Q4 		– Hold
0
– – – 6730
2022
Q3 		– Hold
0
– – – 6609
2022
Q2 		– Sell
-11
Closed -$20.8K – 6636
2022
Q1 		$24K Buy
11
+2
+22% +$4.41K ﹤0.01% 6030
2021
Q4 		$21K Hold
9
– – ﹤0.01% 6198
2021
Q3 		$46K Sell
9
-3
-25% -$22.6K ﹤0.01% 5860
2021
Q2 		$142K Buy
+12
New +$125K ﹤0.01% 5403

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

JP Morgan Chase's GTBP Position: Q2 2026 in Review

JP Morgan Chase held its GT Biopharma (GTBP) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7879.

JP Morgan Chase first reported a position in GTBP in Q2 2021 and has held it in 5 quarters since. The position peaked at $142K in Q2 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • JP Morgan Chase held 0 shares of GT Biopharma worth $0 as of Q2 2026.
  • JP Morgan Chase left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7879 holding.
  • JP Morgan Chase first reported a position in GT Biopharma in Q2 2021 and has held it in 5 quarters since.
  • JP Morgan Chase's GT Biopharma position peaked at $142K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.